Elixinol Global Ltd
Elixinol Wellness Limited, a holding company, provides healthy products in Australia, the Americas, and internationally. The company provides human nutrition, human wellness, pet wellness, and superfood ingredients under Hemp Foods Australia, Mt Elephant, The Healthy Chef, Soul Foods, Ananda Equine, and Field Day brands. It distributed through grocery, wholesale, and e-commerce channels for white… Read more
Elixinol Global Ltd (ELLXF) - Net Assets
Latest net assets as of June 2025: $6.96 Million USD
Based on the latest financial reports, Elixinol Global Ltd (ELLXF) has net assets worth $6.96 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($16.58 Million) and total liabilities ($9.61 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $6.96 Million |
| % of Total Assets | 42.01% |
| Annual Growth Rate | -24.93% |
| 5-Year Change | -71.88% |
| 10-Year Change | N/A |
| Growth Volatility | 42.1 |
Elixinol Global Ltd - Net Assets Trend (2016–2024)
This chart illustrates how Elixinol Global Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Elixinol Global Ltd (2016–2024)
The table below shows the annual net assets of Elixinol Global Ltd from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $10.03 Million | +55.15% |
| 2023-12-31 | $6.46 Million | -29.44% |
| 2022-12-31 | $9.16 Million | -51.99% |
| 2021-12-31 | $19.08 Million | -46.49% |
| 2020-12-31 | $35.65 Million | -67.99% |
| 2019-12-31 | $111.38 Million | -22.51% |
| 2018-12-31 | $143.74 Million | +45.06% |
| 2017-12-31 | $99.09 Million | -0.33% |
| 2016-12-31 | $99.42 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Elixinol Global Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 22436300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $228.29 Million | 2276.99% |
| Other Comprehensive Income | $9.61 Million | 95.85% |
| Total Equity | $10.03 Million | 100.00% |
Elixinol Global Ltd Competitors by Market Cap
The table below lists competitors of Elixinol Global Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
AB Kauno Energija
STU:WVJ
|
$1.24 Million |
|
Niocan Inc
PINK:NIOCF
|
$1.24 Million |
|
Jiuzi Holdings Inc
NASDAQ:JZXN
|
$1.24 Million |
|
Ion Energy Ltd
OTCQB:IONGF
|
$1.25 Million |
|
Rotem Shani Entrepreneurship and Investments Ltd
TA:RTSN
|
$1.24 Million |
|
D R HORTON
MU:HO2
|
$1.24 Million |
|
Kioxia Holdings Corporation
F:KI5
|
$1.24 Million |
|
StandardCoin AS
OL:SCOIN
|
$1.24 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Elixinol Global Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 6,462,000 to 10,026,000, a change of 3,564,000 (55.2%).
- Net loss of 1,722,000 reduced equity.
- Share repurchases of 564,000 reduced equity.
- New share issuances of 4,659,000 increased equity.
- Other comprehensive income decreased equity by 432,000.
- Other factors increased equity by 1,623,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.72 Million | -17.18% |
| Share Repurchases | $564.00K | -5.63% |
| Share Issuances | $4.66 Million | +46.47% |
| Other Comprehensive Income | $-432.00K | -4.31% |
| Other Changes | $1.62 Million | +16.19% |
| Total Change | $- | 55.15% |
Book Value vs Market Value Analysis
This analysis compares Elixinol Global Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.24x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.00x to 0.24x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $3.43 | $0.02 | x |
| 2017-12-31 | $0.65 | $0.02 | x |
| 2018-12-31 | $1.09 | $0.02 | x |
| 2019-12-31 | $0.57 | $0.02 | x |
| 2020-12-31 | $0.15 | $0.02 | x |
| 2021-12-31 | $0.05 | $0.02 | x |
| 2022-12-31 | $0.02 | $0.02 | x |
| 2023-12-31 | $0.09 | $0.02 | x |
| 2024-12-31 | $0.06 | $0.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Elixinol Global Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -17.18%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -11.51%
- • Asset Turnover: 0.81x
- • Equity Multiplier: 1.84x
- Recent ROE (-17.18%) is above the historical average (-88.36%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -2.74% | -45183.33% | 0.00x | 1.06x | $-12.62 Million |
| 2018 | -0.60% | -2.32% | 0.24x | 1.07x | $-15.23 Million |
| 2019 | -72.36% | -262.50% | 0.25x | 1.09x | $-91.77 Million |
| 2020 | -293.14% | -696.24% | 0.35x | 1.19x | $-108.07 Million |
| 2021 | -89.24% | -182.32% | 0.37x | 1.33x | $-18.93 Million |
| 2022 | -115.43% | -149.84% | 0.52x | 1.47x | $-11.49 Million |
| 2023 | -116.17% | -90.78% | 0.71x | 1.81x | $-8.15 Million |
| 2024 | -17.18% | -11.51% | 0.81x | 1.84x | $-2.72 Million |
Industry Comparison
This section compares Elixinol Global Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Elixinol Global Ltd (ELLXF) | $6.96 Million | -2.74% | 1.38x | $1.24 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |